Rallybio’s Acquisition of Worldwide License Rights to KY 1066

Wiggin and Dana represented Rallybio Corporation on the acquisition.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, has obtained worldwide exclusive rights to Sanofi’s KY1066, which will be referred to as RLYB331 going forward, a preclinical potentially first-in-class antibody.

Under the terms of the license agreement, Rallybio will make an upfront cash payment of $3 million to Sanofi, in addition to development and commercial milestones, and mid to high single digit royalties on net sales.

RLYB331 has the potential to address a significant unmet need for patients with severe anemia with ineffective erythropoiesis and iron overload, such as beta thalassemia (BT) and a subset of myelodysplastic syndromes (MDS), amongst others.

The transaction expands Rallybio’s pipeline, is strategically consistent with Rallybio’s existing focus on hematology, and aligns with its mission to accelerate the development of life-transforming therapies for patients with severe and rare disorders.

Rallybio plans to prosecute preclinical activities for RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. 

The Wiggin and Dana team consisted of Partner Patti Melick (Picture) and Associate Kelsey Loomis. 

Involved fees earner: Kelsey Loomis – Wiggin & Dana-Nh ; Patti Melick – Wiggin & Dana-Nh ;

Law Firms: Wiggin & Dana-Nh ;

Clients: Rallybio;

Sonia Carcano

Author: Sonia Carcano